Skip to content

Arcus Biosciences RCUS Compensation and benefits

Compensation and benefits at other companies

Incyte logo
IncyteINCY
Summit Therapeutics logo
Summit TherapeuticsSMMT
Eli Lilly logo
Eli LillyLLY
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's compensation and benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's compensation and benefits?
Arcus Biosciences (RCUS) reported compensation and benefits of $19M in Q1 2026.
How has Arcus Biosciences's compensation and benefits changed year-over-year?
Arcus Biosciences's compensation and benefits increased by 11.8% year-over-year, from $17M to $19M.
What is the long-term trend for Arcus Biosciences's compensation and benefits?
Over 3 years (2022 to 2025), Arcus Biosciences's compensation and benefits has grown at a 9.7% compound annual growth rate (CAGR), from $25M to $33M.